Compare iShares MSCI Hong Kong ETF (EWH) vs Mesoblast Limited (MESO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares MSCI Hong Kong ETF vs Mesoblast Limited — how do they compare? iShares MSCI Hong Kong ETF trades at $22.09 (market cap $1.16B), while Mesoblast Limited trades at $14.33 (market cap $1.75B). The key difference: Mesoblast Limited is the larger of the two by market cap, and iShares MSCI Hong Kong ETF is trading nearer its 52-week high, Mesoblast Limited nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold iShares MSCI Hong Kong ETF for 61 Days and Mesoblast Limited for 14 Days on average.
| EWH | MESO | |
|---|---|---|
Market Cap | $1.16B | $1.75B |
Volume | 3,176,523 | 239,027 |
Sector | Broad Market / Factor | Health |
52-Week High | $24.55 | $20.96 |
52-Week Low | $20.66 | $13.19 |
Typical Hold Time | 61 Days | 14 Days |
Enterprise Value | — | $1.83B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
EWH, the iShares MSCI Hong Kong ETF, trades at $21.58, down 0.19% today amid bearish technical signals with moving averages indicating strong selling pressure. The ETF tracks Hong Kong equities, which have faced volatility due to Federal Reserve policy and US-Iran tensions, as reflected in recent Hang Seng Index declines. Key support sits at $21 with resistance clustered around $22. Financial ratios are unavailable in the current dataset.
Outlook remains cautious given bearish technicals and macroeconomic headwinds impacting Hong Kong markets. Opportunities exist if geopolitical tensions ease and technology stocks rebound, but risks include prolonged Fed tightening and China economic struggles. Investors should monitor Hang Seng Index momentum and institutional flow trends for directional cues.
MESO trades at $13.94, up 2.42% with bearish technical signals from moving averages. The company reported substantial revenue growth to $120 million in 2026 but remains unprofitable with a -47.82% net margin. Recent FDA approval for Ryoncil potency assay and completion of Phase 3 back pain trial represent significant operational milestones. Cash position remains strong at $161.16 million, though debt levels require monitoring.
While MESO shows promising revenue growth and pipeline progress, persistent losses and negative ROE present fundamental challenges. Analyst consensus leans bullish with 45% buy ratings, but technical indicators suggest near-term caution. The stock offers speculative growth potential contingent on successful commercialization and path to profitability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About iShares MSCI Hong Kong ETF
EWH tracks the MSCI Hong Kong 25/50 Index, providing broad exposure to large and mid-cap companies listed in Hong Kong. It focuses on the established pillars of the local economy, with heavy weightings in financials, real estate, and utilities, serving as a single-country diversification tool.
Read more on EWH →About Mesoblast Limited
Mesoblast Limited is a global leader in allogeneic cellular medicines. The company develops innovative, commercially-ready mesenchymal lineage cell (MLC) technology for the treatment of various inflammatory and cardiovascular conditions. Their pipeline focuses on leveraging the anti-inflammatory, tissue repair, and immune-modulating properties of these cells for diseases with high unmet medical needs, such as acute graft versus host disease (aGVHD) and chronic heart failure.
Read more on MESO →
